請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16603
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳進庭(Chin-Tin Chen) | |
dc.contributor.author | Yi-Jou Lee | en |
dc.contributor.author | 李奕柔 | zh_TW |
dc.date.accessioned | 2021-06-07T18:23:15Z | - |
dc.date.copyright | 2020-08-21 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-31 | |
dc.identifier.citation | 1.陳玫延,以微胞包埋chlorin e6之光動力殺菌研究.國立台灣大學,生化科技系研究所碩士論文, 2013 2.D.R. Jenkins. Nosocomial infections and infection control. Medicine. 2017; 45 (10) : 629-633 3.台灣院內感染監視資訊系統(TNIS系統)2018年第2季監視報告 4.H.A. Khan, F.K. Baig, R. Mehboob. Nosocomial infections: epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed 2017;7(5):478–482. 5.Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. Clinical Microbiology Reviews. 2011;24(1):141-173. 6.林小琪,結合光動力殺菌與抗真菌藥物於白色念珠菌的生物效應探討.國立台灣大學,生化科技系研究所碩士論文, 2016 7.Ciurea CN, Kosovski IB, Mare AD, Toma F, Pintea-Simon IA, Man A. Candida and Candidiasis-Opportunism Versus Pathogenicity: A Review of the Virulence Traits. Microorganisms. 2020;8(6):857. 8.Polke M, Hube B, Jacobsen ID. Candida survival strategies. Adv Appl Microbiol. 2015;91:139-235. 9.Diseases and organisms in healthcare settings. Healthcare-associated infections (HAIs).2016. CDC, Atlanta, Georgia 10.Okwu MU, Olley M, Akpoka AO, Izevbuwa OE. Methicillin-resistant Staphylococcus aureus (MRSA) and anti-MRSA activities of extracts of some medicinal plants: A brief review. AIMS Microbiol. 2019;5(2):117-137. 11.Lakhundi S, Zhang K. Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin Microbiol Rev. 2018;31(4):e00020-18. 12.Cannon RD, Lamping E, Holmes AR, et al. Candida albicans drug resistance another way to cope with stress. Microbiology. 2007;153(10):3211-3217. 13.Pam VK, Akpan JU, Oduyebo OO, et al. Fluconazole susceptibility and ERG11 gene expression in vaginal candida species isolated from Lagos Nigeria. Int J Mol Epidemiol Genet. 2012;3(1):84-90. 14.da Costa TM, de Oliveira CR, Chambers HF, Chatterjee SS. PBP4: A New Perspective on Staphylococcus aureus β-Lactam Resistance. Microorganisms. 2018;6(3):57. 15.Kapoor G, Saigal S, Elongavan A. Action and resistance mechanisms of antibiotics: A guide for clinicians. J Anaesthesiol Clin Pharmacol. 2017;33(3):300-305. 16.Džidić S, Šušković J, Kos B. Antibiotic resistance mechanisms in bacteria: biochemical and genetic aspects. Food Technol Biotech. 2008;46:11–21 17.Foster TJ. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiology Reviews. 2017;41(3):430-449. 18.Redgrave LS, Sutton SB, Webber MA, Piddock LJ. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends in Microbiology. 2014;22(8):438-445. 19.Salehi B, Stojanović-Radić Z, Matejić J, et al. The therapeutic potential of curcumin: A review of clinical trials. Eur J Med Chem. 2019;163:527-545. 20.Chainani-Wu N. Safety and anti-inflammatory activity of Curcumin: a component of tumeric (Curcuma longa). Journal of Alternative and Complementary Medicine (New York, N.Y.). 2003;9(1):161-168. 21.Teow SY, Liew K, Ali SA, Khoo AS, Peh SC. Antibacterial Action of Curcumin against Staphylococcus aureus: A Brief Review. Journal of Tropical Medicine. 2016 ;2016:2853045. 22.Mun SH, Kim SB, Kong R, et al. Curcumin reverse methicillin resistance in Staphylococcus aureus. Molecules. 2014;19(11):18283-18295. 23.Moghadamtousi SZ, Kadir HA, Hassandarvish P, et al. A review on antibacterial, antiviral, and antifungal activity of Curcumin. Biomed Research International. 2014 ;2014:186864. 24.Mun SH, Joung DK, Kim YS, et al. Synergistic antibacterial effect of Curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology. 2013;20(8-9):714-718. 25.S.-M. Tsao and M.-C. Yin. Enhanced inhibitory effect from interaction of Curcumin with amphotericin B or fluconazole against Candida species. Journal of Food and Drug Analysis. 2000;8(3): 208–212 26.Hani U, Shivakumar HG. Solubility enhancement and delivery systems of Curcumin a herbal medicine: a review. Curr Drug Deliv. 2014;11(6):792-804. 27.Yallapu MM, Jaggi M, Chauhan SC. beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf B Biointerfaces. 2010;79(1):113-125. 28.Kudva AK, Manoj MN, Swamy BM, Ramadoss CS. Complexation of amphotericin B and Curcumin with serum albumins: solubility and effect on erythrocyte membrane damage. J Exp Pharmacol. 2010;3:1-6. 29.Safavy A, Raisch KP, Mantena S, et al. Design and development of water-soluble Curcumin conjugates as potential anticancer agents. J Med Chem. 2007;50(24):6284-6288. 30.Qiu X, Du Y, Lou B, et al. Synthesis and identification of new 4-arylidene Curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway. J Med Chem. 2010;53(23):8260-8273. 31.Ferrari E, Lazzari S, Marverti G, Pignedoli F, Spagnolo F, Saladini M. Synthesis, cytotoxic and combined cDDP activity of new stable curcumin derivatives. Bioorg Med Chem. 2009;17(8):3043-3052. 32.Wan S, Sun Y, Qi X, Tan F. Improved bioavailability of poorly water-soluble drug Curcumin in cellulose acetate solid dispersion. AAPS PharmSciTech. 2012;13(1):159-166. 33.Allawadi D, Singh N, Singh S, Arora S. Solid dispersions: a review on drug delivery system and solubility enhancement. Int J Pharm Sci Res. 2013;4:2094-105. 34.Liu L, Sun L, Wu Q, et al. Curcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasis. Int J Pharm. 2013;443(1-2):175-182.. 35.Feng T, Wei Y, Lee RJ, Zhao L. Liposomal Curcumin and its application in cancer. Int J Nanomedicine. 2017;12:6027-6044. 36.KZ, Sukamtoh E, Xiao H, McClements DJ, Zhang G. Curcumin: Recent Advances in the Development of Strategies to Improve Oral Bioavailability. Annu Rev Food Sci Technol. 2019;10:597-617. 37.Takahashi M, Uechi S, Takara K, Asikin Y, Wada K. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated Curcumin. J Agric Food Chem. 2009;57(19):9141-9146. 38.Jiang T, Liao W, Charcosset C. Recent advances in encapsulation of Curcumin in nanoemulsions: A review of encapsulation technologies, bioaccessibility and applications. Food Res Int. 2020;132:109035. 39.Yu H, Huang Q. Improving the oral bioavailability of Curcumin using novel organogel-based nanoemulsions. J Agric Food Chem. 2012;60(21):5373-5379. 40.Li Q, Zhai W, Jiang Q, et al. Curcumin-piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharm. 2015;490(1-2):22-31. 41.Setthacheewakul S, Mahattanadul S, Phadoongsombut N, Pichayakorn W, Wiwattanapatapee R. Development and evaluation of self-microemulsifying liquid and pellet formulations of Curcumin, and absorption studies in rats. Eur J Pharm Biopharm. 2010;76(3):475-485. 42.C. Righeschi, M.C. Bergonzi, B. Isacchi, C. Bazzicalupi, P. Gratteri, A.R. BiliaEnhanced curcumin permeability by SLN formulation: the PAMPA approach. LWT – Food Sci. Technol.. 2016 ;66 : 475-483 43.Ji H, Tang J, Li M, Ren J, Zheng N, Wu L. Curcumin-loaded solid lipid nanoparticles with Brij78 and TPGS improved in vivo oral bioavailability and in situ intestinal absorption of Curcumin. Drug Deliv. 2016;23(2):459-470. 44.Dhivya S, Rajalakshmi AN. Curcumin Nano drug delivery systems: A Review on its type and therapeutic application. PharmaTutor. 2017; 5(12); 30-39 45.Chen LC, Chen YC, Su CY, Wong WP, Sheu MT, Ho HO. Development and Characterization of Lecithin-based Self-assembling Mixed Polymeric Micellar (saMPMs) Drug Delivery Systems for Curcumin. Sci Rep. 2016;6:37122. 46.Clinical and Laboratory Standardrs Institute. CLSI Document M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Tenth Edition. 2015. Wayne, Pa, USA: CLSI 47.Clinical and Laboratory Standardrs Institute. CLSI Document M27-A3. Reference Method for Broth Dilution Antifungal Susceptibility. Testing of Yeasts; Approved Standard—Third Edition. 2008. Wayne, Pa, USA: CLSI 48.Bassolé IH, Lamien-Meda A, Bayala B, et al. Chemical composition and antimicrobial activity of Cymbopogon citratus and Cymbopogon giganteus essential oils alone and in combination. Phytomedicine. 2011;18(12):1070-1074. 49.Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: An Overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029. 50.Davis BD, Chen LL, Tai PC. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides. Proceedings of the National Academy of Sciences of the United States of America. 1986;83(16):6164-6168. 51.M.P Mingeot-Leclercq, Y Glupczynski, P.M Tulkens Aminoglycosides: Activity and resistance. Antimicrob Agents Chemother. 1999; 43(4): 727–737. 52.Ramirez, M. S., and Tolmasky, M. E. Aminoglycoside modifying enzymes. Drug Resist Updat. 2010; 13(6): 151–171. 53.Gade ND, Qazi MS. Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand? Journal of Laboratory Physicians. 2013;5(2):109-112. 54.Campos JM, Gill CJ, Hare RS, Miller GH. Effect of NaCl supplementation of Mueller-Hinton broth on susceptibility of staphylococci to aminoglycosides. Antimicrobial Agents and Chemotherapy. 1986;29(1):152-154. 55.Martins CV, da Silva DL, Neres AT, et al. Curcumin as a promising antifungal of clinical interest. J Antimicrob Chemother. 2009;63(2):337-339. 56.Neelofar K, Shreaz S, Rimple B, Muralidhar S, Nikhat M, Khan LA. Curcumin as a promising anticandidal of clinical interest. Can J Microbiol. 2011;57(3):204-210. 57.Khan N, Shreaz S, Bhatia R, et al. Anticandidal activity of curcumin and methyl cinnamaldehyde. Fitoterapia. 2012;83(3):434-440. 58.Sharma M, Manoharlal R, Negi AS, Prasad R. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res. 2010;10(5):570-578. 59.Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47(10):3149-3154. 60.Teow SY, Ali SA. Synergistic antibacterial activity of Curcumin with antibiotics against Staphylococcus aureus. Pak J Pharm Sci. 2015;28(6):2109-2114. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/16603 | - |
dc.description.abstract | 白色念珠菌(Candida albicans)及金黃色葡萄球菌(Staphylococcus aureus)為造成院內感染的常見菌株,且其在臨床上的治療也面臨抗藥性的問題。開發天然化合物或其衍生物來作為抗菌藥物,被認為是一種可行的研究方向。其中,從薑黃(Curcuma longa)的有效成分中萃取出的薑黃素(Curcumin)具安全有效的生物活性,如抗發炎,抗氧化等等;另外,薑黃素具廣泛的抗微生物活性,包括抗菌和抗真菌特性以及影響其生物膜形成的能力,且目前已有文獻發現,高濃度的薑黃素對白色念珠菌及金黃色葡萄球菌的懸浮細胞皆具有抗菌活性。本研究工作主要是利用實驗室既有配方所製備而成的Curcumin對白色念珠菌及金黃色葡萄球菌的抗菌能力進行測試。實驗結果發現相較溶解於DMSO的Curcumin,實驗室製備的Curcumin配方對白色念珠菌具較高的抑菌效果;而雖然針對金黃色葡萄球菌須採用較高濃度的劑量才具明顯抑菌能力,但在低劑量的情形下尚可嘗試結合臨床常用抗菌藥物的方式增強其抑菌效果。因此,本研究之目的除了利用實驗室製備的Curcumin配方測試對白色念珠菌及金黃色葡萄球菌的抗菌能力外,也進一步比較其結合臨床常用抗菌藥物(Ampicillin、Gentamicin及Fluconazole)對這兩種菌株之抑菌效果外,也比較這一配方在具抗藥性的菌株(Methicillin-resistant Staphylococcus aureus, MRSA)的殺菌能力。結果發現在結合臨床藥物及Curcumin配方後,發現可有效降低所需劑量或能達到全殺之抗菌效果。另外,為瞭解這一與臨床藥物的增強效果是否僅針對單一菌株具專一性,故同時測試同為革蘭氏陽性菌的表皮葡萄球菌(Staphylococcus epidermidis )之抗菌能力,而實驗結果也發現具有相同的效力。 | zh_TW |
dc.description.abstract | Candida albicans and Staphylococcus aureus are common strains in nosocomial infections, and both of them have developed drug resistance to antibiotics. Curcumin, the active ingredients of Curcuma longa, has been demonstrated its biological activities, such as anti-inflammatory and antioxidant, etc. Besides, Curcumin also has a wide range of antimicrobial activities, including antibacterial, antifungal properties, and the stability of microbial biofilm. It has been shown that high dose of Curcumin has antimicrobial activities against the planktonic cells of Candida albicans and Staphylococcus aureus. The purpose of this study was to investigate the antimicrobial activities of a formulated curcumin against Candida albicans and Staphylococcus aureus. We found that formulated curcumin has higher antifungal activities than curcumin dissolved in DMSO against Candida albicans. Although higher dose of formulated curcumin was required for Staphylococcus aureus planktonic cells, we found that the combination of formulated curcumin and ampicillin has additive antibacterial activities. This formulated curcumin combined with fluconazole has simialr additive cytotoxicity against Candida albicans. Finally, we showed that this additive bactericidal activity could also be verified in other clinical drugs such as gentamicin as well as against Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T18:23:15Z (GMT). No. of bitstreams: 1 U0001-2707202011083400.pdf: 2146812 bytes, checksum: 142a3debd4da4eb37892903288a30161 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 目錄 致謝 x 中文摘要 xi Abstract xii 第一章、緒論 1 1. 院內感染 1 1.1簡介 1 1.2院內感染的常見菌株 1 1.2-1. 真菌 1 1.2-1-1白色念珠菌 ( Candida albicans ) 1 1.2-2. 細菌 2 1.2-2-1金黃色葡萄球菌 ( Staphylococcus aureus ) 2 2.抗生素及抗真菌劑 3 2.1抗真菌藥物 4 2.1-1氟化嘧啶類( fluorinated pyrimidine ) 4 2.1-2多烯類( polyenes ) 4 2.1-3棘白菌素類(echinocandins)及環脂肽類(cyclic lipopeptides) 4 2.1-4 Azole類抗真菌劑 4 2.2 抗生素 5 2.2-1干擾細胞壁合成藥物 5 2.2-2-1 30S次單元的抑製劑 5 2.2-2-2 50S次單元的抑製劑 6 2.2-3-1 DNA複製抑製劑 6 2.2-3-2葉酸代謝抑製劑 6 3. 薑黃素(Curcumin) 7 3.1簡介 7 3.2薑黃素的抗微生物作用 7 3.2-1抗菌作用 7 3.2-2抗真菌作用 8 3.2-3薑黃素與抗生素對金黃色葡萄球菌的協同作用 8 3.2-4薑黃素與抗真菌藥物對白色念珠菌的協同作用 9 3.3薑黃素臨床應用之挑戰 9 3.3-1薑黃素溶解度的改良 9 3.3-2薑黃素生物利用度的改良 10 4. 實驗動機與目的 13 第二章、材料與方法 14 1.藥品 14 2.儀器 14 3.菌種來源與保存 15 3.1菌種來源 15 3.2菌種保存與活化 15 3.2-1菌種活化 15 3.2-2菌種保存 16 4.實驗方法 16 4.1藥品配置 16 4.1-1抗生素 16 4.1-2抗真菌藥物 16 4.1-3 CUR/MEF 2020及MEF 2020 16 4.2懸浮菌體培養 17 4.3細菌懸浮菌體殺菌實驗 17 4.4白色念珠菌懸浮菌體殺菌實驗 17 4.5最小抑菌濃度(Minimum inhibitory concentration, MIC)試驗 18 4.5-1抗微生物藥物配置 18 4.5-1-1抗生素 18 4.5-1-2抗真菌藥物 18 4.5-1-3 CUR/MEF 2020及MEF 2020 18 4.5-2接種菌量 19 4.5-2-1細菌 19 4.5-2-2白色念珠菌 19 4.5-3 培養基 19 4.5-3-1細菌 19 4.5-3-2白色念珠菌 19 4.5-4 結果判讀 20 4.6棋盤格殺菌試驗(Checkerboard test) 20 4.7殺菌時間曲線試驗( Time-kill assay ) 21 4.8統計分析 21 第三章、實驗結果 22 3.1薑黃素與其溶解性 22 3.2不同濃度的薑黃素(Curcumin)及formulated curcumin對金黃色葡萄球菌( Staphylococcus aureus )及白色念珠菌( Candida albicans )懸浮細胞的殺菌效果 22 3.2-1 CUR/DMSO和CUR/MEF 2020對金黃色葡萄球菌的殺菌效果 22 3.2-2 CUR/DMSO和CUR/MEF 2020對白色念珠菌的殺菌效果 23 3.3不同濃度的CUR/MEF 2020對金黃色葡萄球菌懸浮細胞的有效抑菌測試 23 3.4臨床藥物Ampicillin對金黃色葡萄球菌懸浮細胞的殺菌效果 24 3.5 CUR/MEF 2020結合Ampicillin對金黃色葡萄球菌懸浮細胞的抑菌效果 24 3.6臨床藥物Fluconazole對白色念珠菌懸浮細胞的殺菌效果 25 3.7 CUR/MEF 2020結合Fluconazole對白色念珠菌懸浮細胞的殺菌測試 25 3.8金黃色葡萄球菌懸浮細胞的殺菌時間曲線試驗(Time-kill assay) 26 3.9 CUR/MEF 2020對金黃色葡萄球菌懸浮細胞的殺菌時間曲線試驗( Time-kill assay ) 26 3.10常用之薑黃素溶劑DMSO及賦形劑MEF 2020對金黃色葡萄球菌及白色念珠菌懸浮細胞的殺菌效果 27 3.11稀釋8000倍的MEF 2020結合不同濃度的Ampicillin對金黃色葡萄球菌懸浮細胞的殺菌測試 28 3.12稀釋8000倍的MEF 2020結合不同濃度的Fluconazole對白色念珠菌懸浮細胞的殺菌測試 28 3.13 稀釋8000倍MEF 2020結合Gentamicin對金黃色葡萄球菌懸浮細胞的殺菌效果 28 3.14 稀釋8000倍的MEF 2020結合不同濃度的臨床藥物對金黃色葡萄球菌(MRSA)懸浮細胞的殺菌效果 29 3.15稀釋8000倍的MEF 2020結合不同濃度的臨床藥物對表皮葡萄球菌( S. epidermidis )懸浮細胞的殺菌效果 30 3.16 最小抑菌濃度試驗( MIC ) 30 3.16-1 金黃色葡萄球菌及抗藥性金黃色葡萄球菌的藥物敏感性試驗 31 3.16-2 白色念珠菌的藥物敏感性試驗 31 3.17棋盤格殺菌試驗 32 3.17-1 金黃色葡萄球菌及抗藥性金黃色葡萄球菌的棋盤格殺菌試驗 32 3.17-2白色念珠菌的棋盤格殺菌試驗 33 第四章、討論 34 4.1 CUR/DMSO和CUR/MEF 2020對金黃色葡萄球菌和白色念珠菌的殺菌效果探討 34 4.2 CUR/MEF 2020結合Ampicillin對金黃色葡萄球菌懸浮細胞的抑菌效果 34 4.3 CUR/MEF 2020結合Fluconazole對白色念珠菌懸浮細胞的殺菌測試 35 4.4 金黃色葡萄球菌懸浮細胞的殺菌時間曲線試驗 35 4.5 賦形劑MEF 2020對金黃色葡萄球菌及白色念珠菌懸浮細胞的殺菌效果 36 4.6 稀釋8000倍 MEF 2020結合不同濃度的Fluconazole對白色念珠菌懸浮細胞的殺菌探討 36 4.7 稀釋8000倍 MEF 2020結合Gentamicin對金黃色葡萄球菌懸浮細胞的殺菌效果 37 4.8 稀釋8000倍的MEF 2020結合不同濃度的臨床藥物對金黃色葡萄球菌(MRSA)懸浮細胞的殺菌效果 37 4.9 稀釋8000倍的MEF 2020結合不同濃度的臨床藥物對表皮葡萄球菌( S. epidermidis )懸浮細胞的殺菌效果 39 4.10 最小抑菌濃度試驗( MIC ) 40 4.11棋盤格殺菌試驗之探討 42 第五章、結論 44 第六章、未來方向 45 結果圖表 46 參考文獻 70 | |
dc.language.iso | zh-TW | |
dc.title | 探討薑黃素製劑對金黃色葡萄球菌和白色念珠菌的抗微生物活性 | zh_TW |
dc.title | Investigate the Antimicrobial Activity of Formulated Curcumin against Staphylococcus aureus and Candida albicans | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧麗珍(Lee-Jene Teng),吳亘承(Hsuan-Chen Wu) | |
dc.subject.keyword | 白色念珠菌,金黃色葡萄球菌,表皮葡萄球菌,薑黃素製劑,抗微生物活性,臨床藥物,加成作用, | zh_TW |
dc.subject.keyword | Candida albicans,Staphylococcus aureus,Staphylococcus epidermidis,Formulated Curcumin,Antimicrobial activity,clinical drugs,additivity, | en |
dc.relation.page | 76 | |
dc.identifier.doi | 10.6342/NTU202001897 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-07-31 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 生化科技學系 | zh_TW |
顯示於系所單位: | 生化科技學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2707202011083400.pdf 目前未授權公開取用 | 2.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。